Stock Scorecard



Stock Summary for Sanofi (SNY) - $50.14 as of 10/3/2025 3:25:20 PM EST

Total Score

17 out of 30

Safety Score

80 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for SNY

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for SNY

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for SNY

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for SNY

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for SNY (80 out of 100)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 9
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 6
Operating Margin (Max of 10) 4
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 8
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for SNY

Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September 10/5/2025 12:41:00 PM
Can Galafold Drive Amicus' Growth Through the Rest of 2025? 10/2/2025 1:40:00 PM
Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing 10/1/2025 2:17:00 PM
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline 10/1/2025 1:38:00 PM
Inventiva Appoints Andrew Obenshain as Chief Executive Officer 10/1/2025 6:30:00 AM
Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse? 9/29/2025 2:04:00 PM
Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026 - GSK ( NYSE:GSK ) 9/29/2025 2:00:00 PM
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza 9/29/2025 12:28:00 PM
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab 9/28/2025 4:04:00 PM
Where Will Recursion Pharmaceuticals Be in 5 Years? 9/28/2025 2:00:00 PM

Financial Details for SNY

Company Overview

Ticker SNY
Company Name Sanofi
Country USA
Description Sanofi ADR is a global healthcare leader headquartered in Paris, France, specializing in the research, development, manufacturing, and marketing of innovative therapeutic solutions across various therapeutic areas, including specialty care, vaccines, and consumer healthcare. With a robust pipeline of biopharmaceutical products and a commitment to addressing unmet medical needs, Sanofi operates in over 100 countries, strategically positioning itself in both established and emerging markets. The company's strong focus on digital transformation and sustainability further enhances its competitive edge in the rapidly evolving healthcare landscape, making it a key player for institutional investors seeking long-term growth opportunities.
Sector Name HEALTHCARE
Industry Name DRUG MANUFACTURERS - GENERAL
Most Recent Quarter 6/30/2025
Next Earnings Date 10/24/2025

Stock Price History

Last Day Price 50.14
Price 4 Years Ago 42.68
Last Day Price Updated 10/3/2025 3:25:20 PM EST
Last Day Volume 3,729,069
Average Daily Volume 3,565,094
52-Week High 57.57
52-Week Low 43.86
Last Price to 52 Week Low 14.32%

Valuation Measures

Trailing PE 16.85
Industry PE 26.58
Sector PE 41.81
5-Year Average PE 12.91
Free Cash Flow Ratio 7.96
Industry Free Cash Flow Ratio 38.57
Sector Free Cash Flow Ratio 30.43
Current Ratio Most Recent Quarter 1.27
Total Cash Per Share 6.30
Book Value Per Share Most Recent Quarter 57.52
Price to Book Ratio 1.49
Industry Price to Book Ratio 10.68
Sector Price to Book Ratio 32.30
Price to Sales Ratio Twelve Trailing Months 2.71
Industry Price to Sales Ratio Twelve Trailing Months 3.95
Sector Price to Sales Ratio Twelve Trailing Months 20.26
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 2,437,058,000
Market Capitalization 122,194,088,120
Institutional Ownership 10.27%

Dividends

Ex-Dividend Date 5/9/2025
Previous Dividend Amount 2.0369
Current Dividend Amount 2.2122
Total Years Dividend Increasing 2
Trailing Annual Dividend Rate 2.21
Trailing Annual Dividend Yield 4.41%
Forward Annual Dividend Rate 2.21
Forward Annual Dividend Yield 4.41%
5-Year Dividend Payments Count 6
3-Year Average Dividend Yield 4.28%
5-Year Average Dividend Yield 4.29%
1-Year Dividend Growth Rate Percentage 8.60%
3-Year Dividend Growth Rate Percentage 7.90%
5-Year Dividend Growth Rate Percentage 3.49%
All-Time Dividend Growth Rate Percentage 8.17%
Dividend Payout Ratio 73.25%

Income Statement

Quarterly Earnings Growth YOY 266.60%
Annual Earnings Growth 2.96%
Reported EPS 12 Trailing Months 3.02
Reported EPS Past Year 1.93
Reported EPS Prior Year 4.12
Net Income Twelve Trailing Months 9,126,000,000
Net Income Past Year 5,560,000,000
Net Income Prior Year 5,400,000,000
Quarterly Revenue Growth YOY -5.70%
5-Year Revenue Growth 3.31%
Operating Margin Twelve Trailing Months 18.00%

Balance Sheet

Total Cash Most Recent Quarter 15,359,000,000
Total Cash Past Year 7,441,000,000
Total Cash Prior Year 8,710,000,000
Net Cash Position Most Recent Quarter 2,159,000,000
Net Cash Position Past Year -4,350,000,000
Long Term Debt Past Year 11,791,000,000
Long Term Debt Prior Year 14,347,000,000
Total Debt Most Recent Quarter 13,200,000,000
Equity to Debt Ratio Past Year 0.87
Equity to Debt Ratio Most Recent Quarter 0.84
Total Stockholder Equity Past Year 77,507,000,000
Total Stockholder Equity Prior Year 74,040,000,000
Total Stockholder Equity Most Recent Quarter 70,008,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 3,555,000,000
Free Cash Flow Per Share Twelve Trailing Months 1.46
Free Cash Flow Past Year 5,886,000,000
Free Cash Flow Prior Year 8,639,000,000

Options

Put/Call Ratio 1.42
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 0.44
RSI 0.00
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 10/4/2025 9:39:37 AM EST